Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms, mismatch repair cancer syndrome 1 | Active, not recruiting | Phase 2 | 2026-10-08 | NCT03607890 | |
| Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 1 | 2026-10-06 | NCT05013216 | |
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | Biliary Tract Neoplasms, Cirrhosis, Familial, with Pulmonary Hypertension, Digestive System Diseases, Digestive System Neoplasms, Extrahepatic Cholangiocarcinoma, Liver Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, biliary tract cancer, biliary tract disorder, carcinoma, carcinoma of the ampulla of vater, cholangiocarcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gallbladder carcinoma, gallbladder disorder, gallbladder neoplasm, liver disorder, neoplasm | Not yet recruiting | Phase 2 | 2026-08-28 | NCT07793253 | |
| KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-07-31 | NCT06411691 | |
| Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder | Active, not recruiting | Phase 1 | 2026-07-27 | NCT04117087 | |
| Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 1 | 2026-06-11 | NCT04658147 | |
| Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 2 | 2026-06-03 | NCT04753879 | |
| NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 | 2026-05-05 | NCT06941857 | |
| DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | fibrolamellar hepatocellular carcinoma | Recruiting | Phase 1 | 2025-12-03 | NCT04248569 |